NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia
Search for other papers by Susan O'Brien in
Current site
Google Scholar
PubMed
Search for other papers by Ellin Berman in
Current site
Google Scholar
PubMed
Search for other papers by Joseph O. Moore in
Current site
Google Scholar
PubMed
Search for other papers by Javier Pinilla-Ibarz in
Current site
Google Scholar
PubMed
Search for other papers by Jerald P. Radich in
Current site
Google Scholar
PubMed
Search for other papers by Paul J. Shami in
Current site
Google Scholar
PubMed
Search for other papers by B. Douglas Smith in
Current site
Google Scholar
PubMed
Search for other papers by David S. Snyder in
Current site
Google Scholar
PubMed
Search for other papers by Hema M. Sundar in
Current site
Google Scholar
PubMed
Search for other papers by Moshe Talpaz in
Current site
Google Scholar
PubMed
Search for other papers by Meir Wetzler in
Current site
Google Scholar
PubMed
The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses in most patients. However, its use is complicated by the development of resistance in some patients. Dose escalation might overcome this resistance if detected early. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib provide effective therapeutic options for managing patients resistant or intolerant to imatinib. Recent studies have shown that dasatinib and nilotinib provide quicker and potentially better responses than standard-dose imatinib when used as a first-line treatment. The goal of therapy for patients with CML is the achievement of a complete cytogenetic response, and eventually a major molecular response, to prevent disease progression to accelerated or blast phase. Selecting the appropriate TKI depends on many factors, including disease phase, primary or secondary resistance to TKI, the agent's side effect profile and its relative effectiveness against BCR-ABL mutations, and the patient's tolerance to therapy. In October 2010, NCCN organized a task force consisting of a panel of experts from NCCN Member Institutions with expertise in the management of patients with CML to discuss these issues. This report provides recommendations regarding the selection of TKI therapy for the management of patients with CML based on the evaluation of available published clinical data and expert opinion among the task force members.
Supplementary Materials
- Supplemental Material (PDF 437 KB)
© 2019-2024 National Comprehensive Cancer Network